Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, JianXin Duan, Yuelong Guo, Stephen W. Erickson and Malcolm A. Smith | ||||||||||||
Title | The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/17/1_Supplement/LB-B16 | ||||||||||||
Abstract Text | Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B16 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OBI-3424 | OBI3424|OBI 3424|TH3424|TH 3424|TH-3424 | OBI-3424 (TH 3424) is an AKR1C3-activated prodrug that is converted to a DNA alkylating agent, resulting in tumor cell death (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B16, PMID: 31015346). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|